Lineage Cell Therapeutics, Inc. LCTX
1.02 USD +0.01 +1.39%
As of Nov 3, 10:20 AM ET
- YTD
- -38.68%
- 1 year
- -47.76%
- Open
- 1.02
- Prev close
- 1.01
- Mkt cap
- 259.23M
- Vol
- 105.89K
- Avg vol
- 1.27M
- EPS
- -0.19
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.01
- High
- 1.04
- Forward P/E
- -3.66
- Beta
- 1.28
- Short ratio
- 35.21
- Inst. own
- 50.56%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.7364
- 200-d avg
- 0.96025
- 1y target
- 4.83
5D chart
Chart tools
Chart is warming up
The five-day price history for LCTX has not been loaded yet. Try again in a moment.
Altman Z-Score
-3.43 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C-1 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 1
P/E -6.0×
P/S 26.4×
P/B 8.6×
P/FCF -19.8×
EV/EBITDA -5.1×
EV/Sales 23.8×
FCF Yield -5.1%
Gross Margin 94.2%
Operating Margin -149.6%
Net Margin -436.5%
ROE -142.6%
ROIC -19.7%
ROA -56.4%
Revenue 53.2%
Operating Income -1.4%
EPS (diluted) -201.1%
Free Cash Flow 17.8%
Current Ratio 5.2×
Quick Ratio 5.2×
Debt / Equity 0.1×
Net Debt / EBITDA 0.6×
Interest Coverage 0.0×
Dividend Yield 0.0%
Payout Ratio 0.0%
Annual · latest fiscal year ends 2025-12-31